论文部分内容阅读
目的:系统评价前哨淋巴结(SLN)检测在卵巢癌中的可行性和有效性。方法:在中国知网、万方数据库、维普、PubMed、Embase、web of science、Cochrane library检索发表时间为2000年1月1日至2020年7月29日的关于卵巢癌SLN的研究。对纳入的文献进行质量评价及数据提取，计算SLN的显影率、灵敏度及阴性预测值。结果:纳入8项前瞻性单臂研究，异质性n I2＝57.41%>50%，且n P50%, and then P<0.1. A total of 96 patients with ovarian cancer [Stage International Federation of Gynecology and Obstetrics (FIGO)Ⅰ-Ⅱ] were included, of whom 93 completed systematic pelvic and para-aortic lymphadenectomy after SLN detection. The most common tracers were technetium-99m radioactive colloid (n 99Tcn m), blue dye or indocyanine green (ICG), and the most common injection sites were the infundibulopelvic ligaments and the proper ovarian ligaments. The SLN detection rate was 88.5%(85/96) and the average number was 2-3. SLN was found in the ipsilateral or contralateral regions of the tumor, 40.8%(31/76) was found only in the para-aortic, 14.5%(11/76) was found only in the pelvic, and 44.7%(34/76) was found only in the para-aortic and pelvic region. The sensitivity was 90.9%(10/11) and the negative predictive value was 98.8%(82/83) of lymph node metastasis.n Conclusions:SLN detection for ovarian neoplasms is feasible, and whether it can effectively predict lymph node status of ovarian cancer still needs large sample, multi-center, prospective clinical studies to further verify.